Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!

Subscribe!

Ms: too little, too soon

MagazineFebruary 1997 (Vol. 7 Issue 11)Ms: too little, too soon

Neurologists are playing a high risk strategy by introducing the drug interferon beta-1b into their general treatment of multiple sclerosis on the basis of just one small trial, a leading physician has warned

Neurologists are playing a high risk strategy by introducing the drug interferon beta-1b into their general treatment of multiple sclerosis on the basis of just one small trial, a leading physician has warned.

Richard Richards, from the Department of Public Health and Clinical Practice in Mansfield, says the drug can only at best delay disability, but not prevent it.

He says that a small group of enthusiastic neurologists and an active patient lobby has dictated the granting of a product licence to the drug in Britain. "I have met very few consultants and no general practitioners who support its introduction outside of continuing trials," he writes in the BMJ (BMJ, 1996; 313: 1159).

For more information on multiple sclerosis, see WDDTY vol 1, no 3.


Alternative treatment for gallstones

Gallstones

Sign up for free today

Sign up now to get your FREE 17-point Plan to Great Health

Free membership gives you access to our latest news reports, use of our community area, forums, blogs, readers' health tips and our twice-weekly
e-news letter.

WDDTY Recommends

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, cancer, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2016 WDDTY Publishing Ltd.
All Rights Reserved